Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2023 08:00 ET | Source: Apnimed, Inc.

Apnimed to Present Review of Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
October 11, 2023 08:00 ET | Source: Apnimed, Inc.

Apnimed to Participate in Upcoming October Investor Conferences

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
October 10, 2023 08:30 ET | Source: Apnimed, Inc.

American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea

CAMBRIDGE, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
October 02, 2023 08:00 ET | Source: Apnimed, Inc.

Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors

Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
September 21, 2023 05:30 ET | Source: Apnimed, Inc.

Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

-- LunAIRo Compares AD109 to Placebo Over 6 and 12 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care -- -- Second...
September 18, 2023 08:00 ET | Source: Apnimed, Inc.

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs

CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
September 06, 2023 08:00 ET | Source: Apnimed, Inc.

Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023

-- New Post-Hoc Analysis of MARIPOSA Data on Estimating OSA Endotypes from theOxyhemoglobin Saturation Signal in Patients Dosed with AD109 for 1 Month -- Exploratory Trial on the Impact of...
August 30, 2023 08:00 ET | Source: Apnimed, Inc.

APNIMED to Participate in Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
August 28, 2023 06:00 ET | Source: Apnimed, Inc.

Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company

CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
August 01, 2023 08:00 ET | Source: Apnimed, Inc.

APNIMED to Participate in the 43rd Annual Canaccord Genuity Global Growth Conference

CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right